2025 Targeted Therapies of Lung Cancer (TTLC) - Posters-PP01.46 Clinical outcomes of stage IV lung invasive mucinous adenocarcinoma in the era of immunotherapy: a SEER database analysis

PP01.46 Clinical outcomes of stage IV lung invasive mucinous adenocarcinoma in the era of immunotherapy: a SEER database analysis

Back to course

Pdf Summary

This study analyzes the clinical outcomes of stage IV invasive mucinous adenocarcinoma (IMA) in the context of immunotherapy advancements, utilizing the SEER database which includes cancer incidence and survival statistics from 1992 to 2021. The focus is on comparing IMA with non-IMA adenocarcinomas, noted for their distinct genetic and pathological features. IMA is characterized by a higher frequency of K-RAS mutations and lower EGFR and TP53 expression levels. The study assesses overall survival (OS) and cancer-specific survival (CSS) outcomes before and after 2015, marking the FDA approval of immunotherapy for non-small cell lung cancer (NSCLC).<br /><br />The findings demonstrate that patients with stage IV IMA have poorer clinical outcomes compared to those with non-IMA adenocarcinomas. Notably, immunotherapy did not show a significant benefit for IMA patients. IMA also exhibited unique tumor microenvironment characteristics, with variations in immune cell infiltrations compared to non-IMA. Differences were found in the proportions of B cells, macrophages, T cells, and other immune cells, potentially explaining varied responses to treatment.<br /><br />The study underscores the need for further genomic research and exploration of alternative therapeutic strategies for IMA, given the less favorable outcomes compared to non-IMA and the minimal impact of immunotherapy. It highlights significant disparities in survival rates and cellular compositions between mucinous and non-mucinous adenocarcinomas, suggesting distinct biological behavior and potential treatment pathways. Such detailed insights into the tumor microenvironment and genetic expressions could drive advancements in personalized treatment approaches for advanced-stage IMA.

Asset Subtitle

Wongi Woo

Keywords

stage IV invasive mucinous adenocarcinoma

immunotherapy advancements

SEER database

K-RAS mutations

EGFR expression

TP53 expression

overall survival

cancer-specific survival

tumor microenvironment

personalized treatment